BRG has conducted the DapaTDS-01 clinical trial, a randomized, single-dose, open-label, two-sequence crossover study comparing the bioavailability of an innovative transdermal dapagliflozin system (TTS MTC-D) with the established oral formulation Forxiga® 10 mg film-coated tablets in healthy volunteers.
A distinctive feature of this study was the direct comparison of oral and transdermal drug delivery methods, an approach rarely applied in clinical research. To ensure comprehensive data, the protocol included daily pharmacokinetic assessments and systematic urine collection, making the study particularly demanding for both participants and the clinical team.
The trial demonstrates BRG’s capability to deliver complex early-phase studies under rigorous conditions. By evaluating alternative administration routes, DapaTDS-01 contributes important insights that may support the development of new therapeutic options in diabetes management and improve patient convenience and adherence.
We would like to thank our investigators, clinical staff, and volunteers for their professionalism and commitment throughout the study.